US-based clinical-stage biotechnology firm bluebird bio Inc has raised $600m through a public offering of 3,243,244 shares of its common stock priced at $185 a share.

Underwriters will be granted a 30-day option to buy additional 486,486 shares of common stock.

The firm will use funds to advance the development of its bb2121 product candidate, fund phase one clinical study of a bb21217 product candidate, and for other general corporate purposes.

arGEN-X BV plans to raise €127.46m ($150m) through a public offering of American depositary shares (ADS) priced at €0.10 ($0.12) a unit.

The Netherlands-based clinical-stage biotechnology company plans to use funds to advance development of its drug candidates ARGX-113 and ARGX-110 and for other general corporate purposes.

Austrian clinical-stage biotech firm Hookipa Biotech AG has secured €50m ($58.84m) in a series C funding round.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company will use the funds to perform phase two study of prophylactic Cytomegalovirus (CMV) vaccine in patients who have undergone organ transplants, and extend its technology platform for treatment of prostate cancer.

“Cancer Genetics Inc intends to raise $7m through the private placement of 3.5 million units priced at $2 each.”

NorthSea Therapeutics BV (NST) has secured €25m ($29.46m) in a series A venture funding round.

Based in the Netherlands, NST is a clinical-stage biotech company that develops fatty acid therapeutics.

The company intends to use funds to develop a structurally engineered fatty acid (SEFA) called icosabutate and to carry out clinical and non-clinical toxicology studies.

Synlogic Inc has partnered with biotechnology company Ginkgo BioWorks Inc to develop medicines for neurological and liver disorders.

Synlogic is a developer of probiotic bacteria for treatment of metabolic and inflammatory diseases.

Both companies involved in the transaction are based in the US.

Cancer Genetics Inc intends to raise $7m through the private placement of 3.5 million units priced at $2 each.

Each unit includes one share of common stock and a warrant.

Cancer Genetics is a provider of precision medicine for oncology, and intends to use the proceeds for general corporate purposes.